Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

ARB-001467

Other · developed by Arbutus Biopharma

Phase 2 Most advanced trial (none active)
ABUS Developer
1 Registered trials

What is ARB-001467?

ARB-001467 is an investigational drug studied in Hepatitis B, Chronic.

At a glance

Drug type
Other
Therapy area
Infectious disease
Developer
Arbutus Biopharma Corporation (ABUS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02631096 Phase 2 Hepatitis B, Chronic Completed ABUS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hepatitis B, Chronic

More from Arbutus Biopharma

AB-836 Phase 1 Imdusiran Phase 2 Peg-IFNα-2a Phase 2 PRO-040201 Phase 1 TKM-100201 Phase 1 TKM-100802 Phase 1 TKM-PLK1 Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the ABUS page.

Follow ABUS, the company behind ARB-001467

See ABUS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ABUS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.